About: BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1((-/-)) Mice from Monkeypoxvirus Lethal Challenge

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1((-/-)) Mice from Monkeypoxvirus Lethal Challenge Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1((-/-)) Mice from Monkeypoxvirus Lethal Challenge
Creator	Buller, Mark Donofrio, Gaetano Doronin, Konstantin Franceschi, Valentina Hembrador, Edguardo Parker, Scott Pompilio, Daniela Tebaldi, Giulia Diemert, David Crump, Ryan Estep, Ryan Wong, Scott
Source	PMC
abstract	Monkeypox virus (MPXV) is the etiological agent of human (MPX). It is an emerging orthopoxvirus zoonosis in the tropical rain forest of Africa and is endemic in the Congo-basin and sporadic in West Africa; it remains a tropical neglected disease of persons in impoverished rural areas. Interaction of the human population with wildlife increases human infection with MPX virus (MPXV), and infection from human to human is possible. Smallpox vaccination provides good cross-protection against MPX; however, the vaccination campaign ended in Africa in 1980, meaning that a large proportion of the population is currently unprotected against MPXV infection. Disease control hinges on deterring zoonotic exposure to the virus and, barring that, interrupting person-to-person spread. However, there are no FDA-approved therapies against MPX, and current vaccines are limited due to safety concerns. For this reason, new studies on pathogenesis, prophylaxis and therapeutics are still of great interest, not only for the scientific community but also for the governments concerned that MPXV could be used as a bioterror agent. In the present study, a new vaccination strategy approach based on three recombinant bovine herpesvirus 4 (BoHV-4) vectors, each expressing different MPXV glycoproteins, A29L, M1R and B6R were investigated in terms of protection from a lethal MPXV challenge in STAT1 knockout mice. BoHV-4-A-CMV-A29LgD(106)ΔTK, BoHV-4-A-EF1α-M1RgD(106)ΔTK and BoHV-4-A-EF1α-B6RgD(106)ΔTK were successfully constructed by recombineering, and their capacity to express their transgene was demonstrated. A small challenge study was performed, and all three recombinant BoHV-4 appeared safe (no weight-loss or obvious adverse events) following intraperitoneal administration. Further, BoHV-4-A-EF1α-M1RgD(106)ΔTK alone or in combination with BoHV-4-A-CMV-A29LgD(106)ΔTK and BoHV-4-A-EF1α-B6RgD(106)ΔTK, was shown to be able to protect, 100% alone and 80% in combination, STAT1((-/-)) mice against mortality and morbidity. This work demonstrated the efficacy of BoHV-4 based vectors and the use of BoHV-4 as a vaccine-vector platform.
has issue date	2015-06-18(xsd:dateTime)
bibo:doi	10.1371/journal.pntd.0003850
bibo:pmid	26086739
has license	cc-by
sha1sum (hex)	d480419719edb5f4d35e01306133b919c1474f89
schema:url	https://doi.org/10.1371/journal.pntd.0003850
resource representing a document's title	BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1((-/-)) Mice from Monkeypoxvirus Lethal Challenge
has PubMed Central identifier	PMC4473039
has PubMed identifier	26086739
schema:publication	PLoS Negl Trop Dis
resource representing a document's body	covid:d480419719edb5f4d35e01306133b919c1474f89#body_text
is schema:about of	named entity 'virus' named entity 'study' named entity 'safety' named entity 'meaning' named entity 'infection' named entity 'Challenge' covid:arg/d480419719edb5f4d35e01306133b919c1474f89 named entity 'mice' named entity 'strategy' named entity 'limited' named entity 'MPX' named entity 'FDA-approved' named entity 'tropical' named entity 'demonstrated' named entity 'mortality' named entity 'Antigen' named entity 'Lethal' named entity 'prophylaxis' named entity 'zoonotic' named entity 'vector' named entity 'human population' named entity 'adverse events' named entity 'virus' named entity 'vectors' named entity 'MPX' named entity 'transgene' named entity 'STAT1' named entity 'tropical rain forest' named entity 'vaccine' named entity 'glycoproteins' named entity 'endemic' named entity 'platform' named entity 'intraperitoneally' named entity 'ethidium bromide' named entity 'type 1' named entity 'wild type' named entity 'foreign antigens' named entity 'Bovine' named entity 'environmental degradation' named entity 'stat1' named entity 'pathogens' named entity 'STAT1' named entity 'MVA' named entity 'STAT1' named entity 'morbidity' named entity 'endometritis' named entity 'transcription' named entity 'Protein' named entity 'ORFs' named entity 'Virus' named entity 'smallpox' named entity 'restriction enzyme' named entity 'PBS' named entity 'Hybridization' named entity 'ORF' named entity 'DMEM' named entity 'chloramphenicol' named entity 'contraindicated' named entity 'fibroblast growth factors' named entity 'peptide' named entity 'humidified' named entity 'crystal violet' named entity 'virus' named entity 'homology' named entity 'SalI' named entity 'formalin solution' named entity 'CMV promoter' named entity 'gene delivery' named entity 'CMV' named entity 'glycosaminoglycan'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software